| Objective: To investigate the effects of simvastatin therapy onvascular endothelial fuction and monocyte chemoattractant protein-1(MCP-1) in patients with hyperlipidemia.Methods: 58 patients with hyperlipidemia were randomly dividedinto two groups: control group(28 patients) and simvastatin therpygroup(30 patients,simvastatin 20mg daily for 8 weeks).26 normal healthysubjects were acted as the normal control group. In order to assess thefuction of vascular endothelium by the flow-mediated dilatation (FMD)ofbraehial artery which can be evaluated using high resolution ultralsoundassessment of the brachial artery diameter. The enzyme-linked immunosorbent Assay(ELISA) examined the level of serum MCP-1 before andafter diet or drug therapy. Total cholesterol(TC),triglyceride(TG),lowdensity lipoprotein (LDL)and high density lipoprotein(HDL) for eachgroup were measured.Results: Flow-mediated dilation(FMD) in the control group6.46%±1.21% and simvastatin therpy group 6.31%±1.16% weresignificantly lower than that in the normal group 13.62%±0.77% beforestatin therapy (P＜0.05).The serum MCP-1 in the control group174.89±25pg/ml and simvastatin therpy group 171.13±24pg/ml weresignificantly higher than that in the normal group 110.66±14pg/ml before statin therapy (P＜0.05).The serum MCP-1 was positively related to theserum level of TC (r=0.502,P＜0.05) or LDL(r=0.705,P＜0.05)and FMDwas inversely related to the serum level of MCP-1 (r=-0.562,P＜0.001) inall patients with hyperlipidemia. After 8-week treatment with simvastatin,TC and LDL were decreased significantly(P＜0.05),FMD was increasedfrom 6.31%±1.16% to 12.21%±1.31% (P＜0.05)and MCP-1 wasdecreased from 171.13±24pg/ml to 110.75±16pg/ml(P＜0.05).Aftereight-week treatment with diet control, there were no significant changesof the TC,LDL and FMD and MCP-1(P＞0.05).At the end point oftreatment, FMD was increased in the simvastatin therpy group12.21%±1.31% than in the control group 6.98%±1.23% (P＜0.05)andthe level of mcp-1 was lower in the simvastatin therpy group110.75±16pg/ml than in the control group164.57±30pg/ml (P＜0.05).Aftereight-week therapy, the reduction of serum TC or LDL level was notcorrelated with the improvement of FMD (r=-0.110 and 0.022, P＞0.05).Conclusions: The brachial artery endothelium-dependent dilationwas decreased in patients with hyperlipidemia. The increased serum levelof MCP-1 is correlated with the brachial artery endothelium-dependentdilation dysfunction in patients with hyperlipidemia. Simvastatin couldimproved endothelial function in addition to its lipid-lowering effectpartly. Anti-atherosclerosis's effect of simvastatin may be partly involvedin the reduction of inflammatory marker levels and the improved endothelial function.
|
PDF Full Text Request